The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as well as the Expression of Locomotor Sensitization in Mice
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The gastrointestinal peptide glucagon-like peptide 1 (GLP-1) is known to regulate consummatory behavior and is released in response to nutrient ingestion. Analogues of this peptide recently emerged as novel pharmacotherapies for treatment of type II diabetes since they reduce gastric emptying, glucagon secretion as well as enhance glucose-dependent insulin secretion. The findings that GLP-1 targets reward related areas including mesolimbic dopamine areas indicate that the physiological role of GLP-1 extends beyond food intake and glucose homeostasis control to include reward regulation. The present series of experiments was therefore designed to investigate the effects of the GLP-1 receptor agonist, Exendin-4 (Ex4), on established nicotine-induced effects on the mesolimbic dopamine system in mice. Specifically, we show that treatment with Ex4, at a dose with no effect per se, attenuate nicotine-induced locomotor stimulation, accumbal dopamine release as well as the expression of conditioned place preference in mice. In accordance, Ex4 also blocks nicotine-induced expression of locomotor sensitization in mice. Given that development of nicotine addiction largely depends on the effects of nicotine on the mesolimbic dopamine system these findings indicate that the GLP-1 receptor may be a potential target for the development of novel treatment strategies for nicotine cessations in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In AD, GLP-1(7-36) amide inhibits IL-1β transcription and prevents cognitive dysfunction, amyloid precursor protein synthesis, and cell death.”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [425]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It also enhances learning and memory by promoting long-term potentiation (LTP).425,426”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [425]
Experimental — accuracy not yet measuredIn the citing paper
“preclinical studies suggest GLP-1 may also limit nicotine intake, although these effects of GLP-1 appear to be mediated through distinct mechanisms and brain areas.126,127”
From Nicotinic Acetylcholine Receptor Signaling in the Hypothalamus: Mechanisms Related to Nicotine’s Effects on Food Intake (2020) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,437
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346 · cited 2×
“Given that expression of locomotor sensitization has been suggested to reflect the neurochemical alterations underlying important parts of addiction such as craving and compulsive drug taking [29], GLP-1 receptors may have an important role in the development of addiction.”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“as the hypothalamus and mesolimbic areas [8-11].”
ResultThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“as the hypothalamus and mesolimbic areas [8-11].”
Resultmouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“weight [12-14] via GLP-1 receptors expressed in the hypothalamus [15] and the NTS [16].”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“weight [12-14] via GLP-1 receptors expressed in the hypothalamus [15] and the NTS [16].”
BackgroundGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“Clinically available GLP-1 receptor analogues, such as exenatide and liraglutide, are approved for treatment of type II diabetes since they reduce gastric emptying, glucagon secretion as well as enhance glucose-dependent insulin secretion [43-46].”
BackgroundREVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview
Sanchis‐Segura, C., & Spanagel, R. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00012.x · Cited by 629 · cited 1×
“Given that development of nicotine addiction partly depends on the effects of nicotine on the mesolimbic dopamine system (for review see [2-4]) and that we here show that Ex4 suppresses established nicotine-induced effects on the mesolimbic dopamine system [26,27,31], we hypothesize that GLP-1 receptors within these r…”
BackgroundDrug addiction: the neurobiology of behaviour gone awry
Volkow, N. D., & Li, T.-K. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1539 · Cited by 625 · cited 1×
“Given that development of nicotine addiction partly depends on the effects of nicotine on the mesolimbic dopamine system (for review see [2-4]) and that we here show that Ex4 suppresses established nicotine-induced effects on the mesolimbic dopamine system [26,27,31], we hypothesize that GLP-1 receptors within these r…”
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“425,426 In a murine model of AD, the administration of GLP-1RAs effectively reduced the levels of pathological markers associated with AD.”
BackgroundGLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
GLP-1: Molecular mechanisms and outcomes of a complex signaling system
Smith, N. K., Hackett, T. A., Galli, A., & Flynn, C. R. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.010 · Cited by 188
Vallöf, D., Maccioni, P., Colombo, G., Mandrapa, M., Jörnulf, J. W., Egecioglu, E., Engel, J. A., & Jerlhag, E. (2016) · Addiction Biology · doi:10.1111/adb.12295 · Cited by 150
Self-citationSchmidt, H. D., Mietlicki-Baase, E. G., Ige, K. Y., Maurer, J. J., Reiner, D. J., Zimmer, D. J., Van Nest, D. S., Guercio, L. A., Wimmer, M. E., Olivos, D. R., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.362 · Cited by 148
“Recent studies show that peripheral administration of a GLP-1R agonist attenuates psychostimulant-induced conditioned place preference (CPP) and that these effects are associated with reduced extracellular dopamine levels in the nucleus accumbens of mice (Egecioglu et al, 2013b; Graham et al, 2013).”
BackgroundInfluentialSuchankova, P., Yan, J., Schwandt, M. L., Stangl, B. L., Caparelli, E. C., Momenan, R., Jerlhag, E., Engel, J. A., Hodgkinson, C. A., Egli, M., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.68 · Cited by 146
Self-citationEren-Yazicioglu, C. Y., Yigit, A., Dogruoz, R. E., & Yapici-Eser, H. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.614884 · Cited by 127
Engel, J. A., & Jerlhag, E. (2014) · CNS Drugs · doi:10.1007/s40263-014-0178-y · Cited by 132
“In accordance are the findings that exendin-4, in addition to preventing nicotine reward, blocks nicotine-induced expression of locomotor sensitization in mice [118].”
BackgroundSelf-citationYammine, L., Green, C. E., Kosten, T. R., de Dios, C., Suchting, R., Lane, S. D., Verrico, C. D., & Schmitz, J. M. (2021) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntab066 · Cited by 124
Oxytocin Acting in the Nucleus Accumbens Core Decreases Food Intake
Herisson, F. M., Waas, J. R., Fredriksson, R., Schiöth, H. B., Levine, A. S., & Olszewski, P. K. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12381 · Cited by 104
Phillips, B. W., Veljkovic, E., Peck, M. J., Buettner, A., Elamin, A., Guedj, E., Vuillaume, G., Ivanov, N. V., Martin, F. P., Boué, S., et al. (2015) · Food and Chemical Toxicology · doi:10.1016/j.fct.2015.03.009 · Cited by 111
“secretion and enhance glucose-dependent insulin secretion (Alhadeff et al., 2012; Egecioglu et al., 2013; Turton et al., 1996), our experimental data are not robust enough to explain the observed body weight increases in the pMRTP-exposed mice.”
ResultAlhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102
“As new potential applications for GLP-1 pharmacotherapies emerge in the literature (eg, addiction (Egecioglu et al, 2013; Shirazi et al, 2013; Skibicka, 2013; Sorensen et al, 2015; Suchankova et al, 2015), neurodegenerative diseases (Bao et al, 2015; Holscher, 2014)), it is our hope that this tool…”
BackgroundReddy, I. A., Pino, J. A., Weikop, P., Osses, N., Sørensen, G., Bering, T., Valle, C., Bluett, R. J., Erreger, K., Wortwein, G., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.86 · Cited by 96
Effects of dulaglutide on alcohol consumption during smoking cessation
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023) · JCI Insight · doi:10.1172/jci.insight.170419 · Cited by 94
“Furthermore, GLP-1 agonism has been found to attenuate reward induced by other substances, e.g., psychostimulants (12–14) and nicotine (15, 16).”
BackgroundThomsen, M., Dencker, D., Wörtwein, G., Weikop, P., Egecioglu, E., Jerlhag, E., Fink‐Jensen, A., & Molander, A. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.07.014 · Cited by 100
Self-citationZhang, Y., Kahng, M. W., Elkind, J. A., Weir, V. R., Hernandez, N. S., Stein, L. M., & Schmidt, H. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0531-4 · Cited by 92
“Systemic infusions of exendin-4 also reduce the rewarding effects of alcohol [14], nicotine [15, 16], cocaine [17, 18], and amphetamine [18] in mice.”
BackgroundBruns VI, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107312 · Cited by 89
De Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 77
“Only two pre-clinical investigations on the effects of GLP-1RAs in nicotine misuse were retrieved, both showing less nicotine use and related outcomes (for example, withdrawal-induced hyperphagia) for liraglutide 108 and exendin-4 possibly related to dopamine regulation 106 .”
Gut-brain axis and addictive disorders: A review with focus on alcohol and drugs of abuse
Jerlhag, E. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.005 · Cited by 93
Self-citationHarasta, A. E., Power, J., von Jonquières, G., Karl, T., Drucker, D. J., Housley, G. D., Schneider, M., & Klugmann, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.47 · Cited by 97
“Attenuated dopamine release in the NAc was reported following systemic Ex4 administration (Egecioglu et al, 2013a; Egecioglu et al, 2013c).”
BackgroundResultInfluentialA novel mouse model of glucagon‐like peptide‐1 receptor expression: A look at the brain
Graham, D. L., Durai, H. H., Trammell, T. S., Noble, B. L., Mortlock, D. P., Galli, A., & Stanwood, G. D. (2020) · Journal of Comparative Neurology · doi:10.1002/cne.24905 · Cited by 88
“Data from our lab and others have demonstrated a role for GLP-1R on drug reward (Egecioglu et al., 2013b; Egecioglu, Steensland, et al., 2013; F IGURE 1 Endogenous Glp1r expression within the brain of WT C57Bl6/J mice.”
BackgroundWang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02498-5 · Cited by 83
“Data speci fi c to this study including diagnosis codes and cohort characteristics in aggregated format are included in the manuscript as tables, fi gures, and supplementary fi les.”
BackgroundVallöf, D., Kalafateli, A. L., & Jerlhag, E. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.02.006 · Cited by 84
Self-citationJerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1063033 · Cited by 80
Self-citationTobacco Smoking, Eating Behaviors, and Body Weight: a Review
Chao, A. M., Wadden, T. A., Ashare, R. L., Loughead, J., & Schmidt, H. D. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00253-3 · Cited by 68
Bornebusch, A. B., Fink-Jensen, A., Wörtwein, G., Seeley, R. J., & Thomsen, M. (2019) · eneuro · doi:10.1523/eneuro.0443-18.2019 · Cited by 72
“For CPP, analysis was based on the effect sizes reported for acquisition of CPP using alcohol (Egecioglu et al., 2013c; Vallöf et al., 2016), both analyses yielding a required n 9.”
BackgroundMethodResultInfluentialGLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence
Jerlhag, E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.013 · Cited by 72
Self-citationMontelius, C., Erlandsson, D., Vitija, E., Stenblom, E.-L., Egecioglu, E., & Erlanson-Albertsson, C. (2014) · Appetite · doi:10.1016/j.appet.2014.06.101 · Cited by 72
“Based on the fact that GLP-1 regulates reward-induced behaviour for food ( Dickson et al., 2012; Egecioglu, Engel, & Jerlhag, 2013a, 2013b; Egecioglu et al., 2013), the urge for sweet, salt and fat was evaluated during one day meal tests in the beginning and the end of the study.”
BackgroundSelf-citationEffects of the GLP‐1 Agonist Exendin‐4 on Intravenous Ethanol Self‐Administration in Mice
Sørensen, G., Caine, S. B., & Thomsen, M. (2016) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13199 · Cited by 69
“GLP-1 receptor agonists decreased conditioned place preference to ethanol, sweet foods, nicotine, cocaine and amphetamine (Dickson et al., 2012; Egecioglu et al., 2013a; Egecioglu et al., 2013b, 2013c; Graham et al., 2013; Shirazi et al., 2013; Alhadeff and Grill, 2014; Richard et al., 2015; Vallöf…”
BackgroundInfluentialCentral GLP-1 receptors: Novel molecular targets for cocaine use disorder
Hernandez, N. S., & Schmidt, H. D. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.03.026 · Cited by 63
“4 μg/kg) pretreatment reduced nicotine-induced locomotion, sensitization, CPP and accumbal dopamine release [187].”
BackgroundBrunchmann, A., Thomsen, M., & Fink-Jensen, A. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.03.029 · Cited by 56
Douton, J. E., Augusto, C., Stoltzfus, B., Carkaci-Salli, N., Vrana, K. E., & Grigson, P. S. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000609 · Cited by 60
“GLP-1Rs are found in this area (Merchenthaler et al., 1999) and intra-VTA injections of Ex-4 have been shown to reduce drug-primed reinstatement of cocaine-seeking behavior (Hernandez et al., 2018).”
BackgroundInfluentialVallöf, D., Vestlund, J., & Jerlhag, E. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.020 · Cited by 61
Self-citationSchwartz, A., & Bellissimo, N. (2021) · Appetite · doi:10.1016/j.appet.2021.105260 · Cited by 66
Konanur, V. R., Hsu, T. M., Kanoski, S. E., Hayes, M. R., & Roitman, M. F. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.112771 · Cited by 58
McKay, N. J., Galante, D. L., & Daniels, D. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3267-14.2014 · Cited by 55
“It is, however, involved in other motivated behaviors including fluid and drug intakes (Navarro et al., 1996; Tang-Christensen et al., 1996; McKay et al., 2011; McKay and Daniels, 2013; Egecioglu et al., 2013a, b).”
BackgroundDouton, J. E., Horvath, N., Mills‐Huffnagle, S., Nyland, J. E., Hajnal, A., & Grigson, P. S. (2022) · Addiction Biology · doi:10.1111/adb.13117 · Cited by 54
The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
Zhang, L., Zhang, W., & Tian, X. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2021.1924707 · Cited by 54
“A few studies have shown that, in CPP paradigm, treatment with EX-4 can prevent nicotine induced locomotor stimulation, NAc dopamine release in the accumbent septum and memory consolidation of nicotine reward as well as block nicotine induced locomotor sensitization in mice [181].”
BackgroundTargeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Herman, R. J., & Schmidt, H. D. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114565 · Cited by 62
Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1
Jerlhag, E. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146562 · Cited by 53
Self-citationEngel, J. A., & Jerlhag, E. (2014) · Progress in brain research · doi:10.1016/b978-0-444-63425-2.00009-x · Cited by 62
Self-citationReassessing wanting and liking in the study of mesolimbic influence on food intake
Nicola, S. M. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00234.2016 · Cited by 55
“Based on this interpretational framework, it is reasonable to conclude that ghrelin and GLP-1 influence food wanting.”
BackgroundThe Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Valenta, S. T., Nicastri, A., Perazza, F., Marcolini, F., Beghelli, V., Atti, A. R., & Petroni, M. L. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00331-y · Cited by 55
“In SUD, GLP-1 RAs mitigate abuse by modulating brain reward pathways and dopamine release, particularly within the nucleus accumbens [15, 17, 31].”
Metabolic hormone action in the VTA: Reward-directed behavior and mechanistic insights
Geisler, C. E., & Hayes, M. R. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114236 · Cited by 53
Marquez-Meneses, J. D., Olaya-Bonilla, S. A., Barrera-Carreño, S., Tibaduiza-Arévalo, L. C., Forero-Cárdenas, S., Carrillo-Vaca, L., Rojas-Rodríguez, L. C., Calderón‐Ospina, C., & Rodríguez, J. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115338 · Cited by 57
“Egecioglu et al. (2013) further demonstrated that Ex4 reduced ethanol-induced hy-perlocomotion and abolished the rise in NAc dopamine in mice.”
InfluentialSuchankova, P., Engel, J. A., & Jerlhag, E. (2016) · Alcohol and Alcoholism · doi:10.1093/alcalc/agv100 · Cited by 47
Self-citationFarokhnia, M., Browning, B. D., Crozier, M. E., Sun, H., Akhlaghi, F., & Leggio, L. (2022) · Addiction Biology · doi:10.1111/adb.13211 · Cited by 46
“The positive association with cigarette pack years is also interesting, as research has found the GLP-1 system to be involved in nicotine use as well.(35,36) It is important to note that our 8 of 11 FAROKHNIA ET AL.”
Herman, R. J., Hayes, M. R., Audrain-McGovern, J. E., Ashare, R. L., & Schmidt, H. D. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06376-w · Cited by 47
Zhang, Y., Rahematpura, S., Ragnini, K., Moreno, A., Stecyk, K. S., Kahng, M. W., Milliken, B. T., Hayes, M. R., Doyle, R. P., & Schmidt, H. D. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108599 · Cited by 44
Douton, J. E., Acharya, N. K., Stoltzfus, B., Sun, D., Grigson, P. S., & Nyland, J. E. (2022) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000685 · Cited by 36
An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side
Shevchouk, O. T., Tufvesson‐Alm, M., & Jerlhag, E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.774050 · Cited by 47
Self-citationCalarco, C. A., & Picciotto, M. R. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz010 · Cited by 40
Hansen, H. H., Fabricius, K., Barkholt, P., Mikkelsen, J. D., Jelsing, J., Pyke, C., Knudsen, L. B., & Vrang, N. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.038 · Cited by 42
“We have not characterized this effect further, but it seems less likely that GLP-1 receptor agonists directly modulate striatal dopamine release, as exendin-4 has no effect on extracellular dopamine levels in the rodent nucleus accumbens (Egecioglu et al., 2013, Mietlicki-Baase et al., 2013).”
BackgroundEvans, B., Stoltzfus, B., Acharya, N., Nyland, J. E., Arnold, A. C., Freet, C. S., Bunce, S. C., & Grigson, P. S. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.08.022 · Cited by 39
Falk, S., Petersen, J., Svendsen, C., Leguizamón, C. R. R., Jørgensen, S. H., Krauth, N., Ludwig, M. Q., Lundø, K., Roostalu, U., Skovbjerg, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112466 · Cited by 41
“26,30”
Dixon, T. N., McNally, G. P., & Ong, Z. Y. (2020) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14437 · Cited by 37
Lengsfeld, S., Probst, L., Emara, Y., Werlen, L., Vogt, D., Bathelt, C., Baur, F., Caviezel, B., Vukajlovic, T., Fischer, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105284 · Cited by 40
GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling
Kooij, K. L., Koster, D. I., Eeltink, E., Luijendijk, M. C. M., Drost, L., Ducrocq, F., & Adan, R. A. H. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103925 · Cited by 39
“…peripherally administered GLP-1R agonists, exendin-4 and liraglutide, decreased the intake of alcohol, cocaine and, food and reduced motivation for these substances in a progressive ratio task (Dickson et al., 2012; Egecioglu et al., 2013a, 2013b; S ø rensen et al., 2015; Vall ¨ of et al., 2016).”
InfluentialNeurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse
Schmidt, H. D., Rupprecht, L. E., & Addy, N. (2018) · Complex Psychiatry · doi:10.1159/000494799 · Cited by 36
What is bipolar disorder? A disease model of dysregulated energy expenditure
Mansur, R. B., Lee, Y. L., McIntyre, R. S., & Brietzke, E. M. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.04.006 · Cited by 36
Linking drug and food addiction: an overview of the shared neural circuits and behavioral phenotype
Passeri, A., Municchi, D., Cavalieri, G., Babicola, L., Ventura, R., & Segni, M. D. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1240748 · Cited by 33
Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights
Alves, G. A. M., Teranishi, M., Ortega, A. C. T. D. C. G., James, F., & Arachchige, A. S. P. M. (2025) · Medical Sciences · doi:10.3390/medsci13030136 · Cited by 49
“Jerlhag et. al. further demonstrated that GLP-1RAs suppress alcohol-induced locomotor stimulation and DA release in the NAc, suggesting that GLP-1R signaling can dampen mesolimbic sensitization to ethanol [24].”
InfluentialGlucagon-like peptide-1 receptors and sexual behaviors in male mice
Vestlund, J., & Jerlhag, E. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104687 · Cited by 31
Self-citationSass, M. R., Klausen, M. K., Schwarz, C. R., Rasmussen, L., Giver, M. E. B., Hviid, M., Schilling, C., Zamorski, A., Jensen, A., Gefke, M., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.3639 · Cited by 45
Vallöf, D., Ulenius, L., Egecioglu, E., Engel, J. A., & Jerlhag, E. (2016) · Addiction Biology · doi:10.1111/adb.12355 · Cited by 31
“Furthermore, it was recently shown that peripheral administration of analogues of the anorexic peptide GLP-1 attenuates reward-related behaviors (Egecioglu, Engel & Jerlhag 2013a,2013b; Egecioglu et al. 2013c; Erreger et al. 2012; Graham et al. 2013; Suchankova et al. 2015).”
BackgroundResultSelf-citationDunigan, A. I., & Roseberry, A. G. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100011 · Cited by 32
To Do or Not to Do: Dopamine, Affordability and the Economics of Opportunity
Beeler, J. A., & Mourra, D. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00006 · Cited by 28
The (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 29
Vallöf, D., Vestlund, J., Engel, J. A., & Jerlhag, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154477 · Cited by 29
Self-citationZhu, C., Li, H., Kong, X., Wang, Y., Sun, T., & Wang, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.819470 · Cited by 26
Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Klausen, M. K., Knudsen, G. M., Vilsbøll, T., & Fink‐Jensen, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70004 · Cited by 35
Lee, S. M. L., Li, M., Le, G. H., Teopiz, K. M., Vinberg, M., Ho, R., Au, H. C. T., Wong, S., Valentino, K., Kwan, A. T. H., et al. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00527-9 · Cited by 25
“Rodents were allowed self-administered nicotine, forming nicotine-seeking and withdrawal habits [20, 21].”
InfluentialLong-term functional alterations following prenatal GLP-1R activation
Graham, D. L., Madkour, H. S., Noble, B. L., Schatschneider, C. W., & Stanwood, G. D. (2021) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2021.106984 · Cited by 25
du Hoffmann, J., & Nicola, S. M. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00144 · Cited by 27
“…microinjected D1 and D2 antagonists had very similar behavioral (Hiroi and White, 1991; Ozer et al., 1997; Koch et al., 2000; Yun et al., 2004b; Eiler et al., 2006; Pezze et al., 2007; Lex and Hauber, 2008; Liao, 2008; Nicola, 2010; Shin et al., 2010; Haghparast et al., 2012; Steinberg et al.,…”
BackgroundBinge-like intake of HFD attenuates alcohol intake in rats
SIROHI, S. K., Cleef, A. V., & Davis, J. F. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.10.006 · Cited by 22
A brain reward circuit inhibited by next-generation weight-loss drugs in mice
Godschall, E., Güngül, T. B., Sajonia, I. R., Buyukaksakal, A., Li, O., Ogilvie, S., Keeler, A. B., Tian, G., Shi, Y., Koita, O., et al. (2026) · Nature · doi:10.1038/s41586-026-10444-4 · Cited by 23
Eren, C. Y., Kara, B., Sancak, S., Uysal, S. P., Yazıcı, D., Okuroğlu, N., Whitton, A. E., Rutherford, A. V., & Eser, H. Y. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001409 · Cited by 23
Łupina, M., Talarek, S., Kotlinska, J. H., Gibuła‐Tarłowska, E., Listos, P., & Listos, J. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104616 · Cited by 22
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Coynel, D., Vogt, D. R., Hemkens, L. G., Speich, B., Zanchi, D., Erlanger, T. E., et al. (2023) · Trials · doi:10.1186/s13063-023-07164-9 · Cited by 20
Tongta, S., Sungkaworn, T., & Pathomthongtaweechai, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210974 · Cited by 21
“Peripheral Ex-4 reduces extracellular dopamine levels in the NAc after alcohol, nicotine, and cocaine intake, without affecting baseline dopamine levels, indicating that GLP-1R activation selectively inhibits substance-induced dopamine release while preserving normal dopaminergic tone [151,209].”
Crosstalk between alcohol use disorder and obesity: two sides of the same coin?
Leggio, L., Farokhnia, M., Kenny, P. J., Pepino, M. Y., & Simmons, W. K. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03259-8 · Cited by 18
Salmon Calcitonin Attenuates Some Behavioural Responses to Nicotine in Male Mice
Aranäs, C., Vestlund, J., Witley, S., Edvardsson, C. E., Kalafateli, A. L., & Jerlhag, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.685631 · Cited by 20
Self-citationWhite, B., & Sirohi, S. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128292367240510111746 · Cited by 17
Erina, Y., Yasoshima, Y., & Shimura, T. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.12.034 · Cited by 15
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents
Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vujičić, M., Aranäs, C., Benrick, A., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2025.106119 · Cited by 16
Self-citationExploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation
Yammine, L., de Dios, C., Suchting, R., Green, C. E., Nielsen, D. A., Walss‐Bass, C., & Schmitz, J. M. (2025) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntaf005 · Cited by 14
Yammine, L., Grigson, P. S., Schmitz, J. M., Evans, B., & Hendershot, C. S. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00657-4 · Cited by 15
Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial
Yammine, L., Kosten, T. R., Cinciripini, P. M., Green, C. E., Meininger, J. C., Minnix, J. A., & Newton, T. F. (2018) · Medicine · doi:10.1097/md.0000000000009567 · Cited by 16
“In mice, treatment with a GLP-1 agonist at a dose with no other behavioral effects attenuated nicotine-induced locomotor stimulation, nucleus accumben’s dopamine release, and reduced the expression of nicotine conditioned place preference.([9]) GLP-1 is produced endogenously in the intestinal L-cells and in the hindbr…”
BackgroundCruz, B., Flores, R. J., Uribe, K. P., Espinoza, E. J., Spencer, C. T., Serafine, K. M., Nazarian, A., & O’Dell, L. E. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0306-3 · Cited by 17
“Importantly, a prior study revealed that administration of a GLP-1 receptor agonist (Exendin-4) reduces nicotine-induced CPP, locomotor activity, and increases in NAc dopamine release compared to controls [41].”
Prenatal Effects of Nicotine on Obesity Risks: A Narrative Review
White, O., Roeder, N. M., Blum, K., Eiden, R. D., & Thanos, P. K. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19159477 · Cited by 16
“Similar lack of satiating behavior has been observed involving GLP-1 and nicotine in preclinical models [189].”
BackgroundYammine, L., Verrico, C. D., Versace, F., Webber, H. E., Suchting, R., Weaver, M. F., Kosten, T. R., Alibhai, H., Cinciripini, P. M., Lane, S. D., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072707 · Cited by 13
“24 Further, our recent clinical trial of a GLP-RA extended-release exenatide showed that in the sample of 82 smokers who were prediabetic and/or overweight, 6 weeks treatment with exenatide resulted in a higher probability of abstinence and a lower probability of PCWG, compared with placebo.”
Vestlund, J., Zhang, Q., Shevchouk, O. T., Hovey, D., Lundström, S., Westberg, L., & Jerlhag, E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02209-0 · Cited by 15
Self-citationLu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Klausen, M. K., Kuzey, T., Pedersen, J. N., Justesen, S. K., Rasmussen, L. J. H., Knorr, U., Mason, G. F., Ekstrøm, C. T., Holst, J. J., Koob, G. F., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-086454 · Cited by 14
Urbanik, L. A., Booth, J. L., Acharya, N., Evans, B., & Grigson, P. S. (2024) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000805 · Cited by 12
Metabolic factors modulate effort-based decision-making in major depressive disorder
Gill, H., Badulescu, S., Vincenzo, J. D. D., Tabassum, A., Mckenzie, A., Shah, H., Amin, M., Llach, C.-D., Rosenblat, J. D., McIntyre, R. S., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.090 · Cited by 14
No Change in Serum Incretins Levels but Rise of Leptin Levels After Smoking Cessation: a Pilot Study
Pánková, A., Králíková, E., Kaválková, P., STEPANKOVA, L., Zvolská, K., & Haluzík, M. (2016) · Physiological Research · doi:10.33549/physiolres.933154 · Cited by 12
“Incretins are hormones secreted in the gut in response to food ingestion (Nauck 2011) as well as in the hindbrain (Egecioglu et al. 2013) and help to manage glucose control by regulating insulin and glucagon release (Seino et al. 2010, Madsbad 2014), gastric emptying (Edholm et al. 2010, Deane et…”
BackgroundFortin, S. M., & Roitman, M. F. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.11.021 · Cited by 11
GLP‐1 at the Metabolic–Cognitive Interface: Reward, Affect, and Memory
Gao, S., Décarie-Spain, L., Gu, C., Mazzini, G., Kanoski, S. E., & Borner, T. (2026) · Comprehensive physiology · doi:10.1002/cph4.70129 · Cited by 17
“…the early 2010s, when pioneering work spear-headed by Elisabet Jerlhag and her team showed that systemic administration of Ex-4 reduces alcohol, nicotine, amphetamine, and cocaine-induced hyperactivity, ACB DA release, and conditioned place preference in mice (Egecioglu et al. 2013a, 2013b, 2012).”
Metadata
- Authors
- Egecioglu, E., Engel, J. A., & Jerlhag, E.
- Affiliations
- University of Gothenburg (SE)
- Corresponding author
- Engel, Jörgen A.
- ORCID
- Jerlhag, Elisabet
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-18
- Volume
- 8
- Issue
- 10
- Pages
- e77284
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3799694
- OpenAlex
- W2086172137
- Cited by
- 158
- References
- 52
- Citations by year
- 2026: 22 · 2025: 20 · 2024: 15 · 2023: 18 · 2022: 10 · 2021: 18 · 2020: 5 · 2019: 17 · 2018: 6 · 2017: 2 · 2016: 14 · 2015: 6 · 2014: 5
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Vetenskapsrådet (K2010-80X-21496-01-6, 2009-02782, K2006-21X-04247-33-3)
- Sahlgrenska Universitetssjukhuset (148251)
- Systembolaget Aktiebolag
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- exendin-4, glucagon-like peptide-1, GLP-1 receptor agonists, nicotine, nicotine dependence, mesolimbic dopamine system, locomotor stimulation, locomotor sensitization, conditioned place preference, reward, nicotine cessation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Conditioning, Psychological, Dopamine, Eating, Limbic System, Male, Motor Activity, Nicotine, Nucleus Accumbens, Peptides, Reward, Tobacco Use Disorder, Venoms, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.